Mesothelioma NewsTroVax studied in the treatment of mesothelioma
New York, NY - May 19, 2011
Oxford Biomedica has awarded New York-based pharmaceutical giant Pfizer non-exclusive rights to the diagnostic use of antibodies directed against the tumor antigen 5T4 and an option to sell a diagnosis based on 5T4. BioMedica and Wyeth entered into a therapeutic approach in 2001 was acquired by Pfizer in 2009. This agreement grants rights to Wyeth antibodies directed to the global market for all cancer indications 5T4.
The 5T4 antigen is the objective of Phase II BioMedica therapeutic measures against TroVax cancer vaccine, which is based on a modified vaccinia virus Ankara (MVA), which provides the 5T4 antigen. BioMedica study is to evaluate the effectiveness of TroVax in combination with docetaxel in the treatment of hormone-refractory prostate cancer (HRPC).
In addition, phase I / II study evaluated TroVax treatment with first line chemotherapy for mesothelioma is scheduled to begin in 2011, as the study of patients with ovarian cancer. Malignant mesothelioma is a rare tumor protective lining of the lungs, heart, chest and abdomen, which is almost entirely due to the long-term exposure to asbestos.
Combination therapy of mesothelioma surgery, chemotherapy and radiation, but is not healing. Mesothelioma takes on average 40 years to develop and is asymptomatic until it reaches its later stages, so it is very difficult to diagnose. Mesothelioma is most common, life expectancy is expected to be approximately six months after detection.
Although the phase III study evaluating Trist TroVax in metastatic renal cell carcinoma failed primary endpoint, the results of tests found TroVax subgroups of patients who can be of significant benefit. This led to the development of an algorithm, called the immune response against a substitute (IRS), which "gives us the opportunity to address more effectively respond to the group of patients, and we are sure that this is a novel biomarker to further substantiate the results of the current phase of development TroVax II clinical development, "said Stuart Naylor, Biomedical CSO.
New York, NY - May 19, 2011
Oxford Biomedica has awarded New York-based pharmaceutical giant Pfizer non-exclusive rights to the diagnostic use of antibodies directed against the tumor antigen 5T4 and an option to sell a diagnosis based on 5T4. BioMedica and Wyeth entered into a therapeutic approach in 2001 was acquired by Pfizer in 2009. This agreement grants rights to Wyeth antibodies directed to the global market for all cancer indications 5T4.
The 5T4 antigen is the objective of Phase II BioMedica therapeutic measures against TroVax cancer vaccine, which is based on a modified vaccinia virus Ankara (MVA), which provides the 5T4 antigen. BioMedica study is to evaluate the effectiveness of TroVax in combination with docetaxel in the treatment of hormone-refractory prostate cancer (HRPC).
In addition, phase I / II study evaluated TroVax treatment with first line chemotherapy for mesothelioma is scheduled to begin in 2011, as the study of patients with ovarian cancer. Malignant mesothelioma is a rare tumor protective lining of the lungs, heart, chest and abdomen, which is almost entirely due to the long-term exposure to asbestos.
Combination therapy of mesothelioma surgery, chemotherapy and radiation, but is not healing. Mesothelioma takes on average 40 years to develop and is asymptomatic until it reaches its later stages, so it is very difficult to diagnose. Mesothelioma is most common, life expectancy is expected to be approximately six months after detection.
Although the phase III study evaluating Trist TroVax in metastatic renal cell carcinoma failed primary endpoint, the results of tests found TroVax subgroups of patients who can be of significant benefit. This led to the development of an algorithm, called the immune response against a substitute (IRS), which "gives us the opportunity to address more effectively respond to the group of patients, and we are sure that this is a novel biomarker to further substantiate the results of the current phase of development TroVax II clinical development, "said Stuart Naylor, Biomedical CSO.
